BACKGROUND Neuropsychiatric symptoms of dementia such as depression and apathy in patients with Alzheimer's disease (AD) are associated with a lower quality of life. OBJECTIVE We aimed to determine the efficacy of two antidepressants and one antipathy drug in the treatment of depression and apathy in AD patients. METHODS In the present study, we evaluated the efficacy of sertraline (n = 11; average dose = 31.8 mg), escitalopram (n = 13; average dose = 7.3 mg), and nicergoline (n = 9; average dose = 14.5 mg) in treating depression and apathy over a period of 3 months (M).The 33 patients with AD demonstrated high Geriatric Depression Scale (GDS) (>5) or a high Apathy Scale (AS) (>16) scores. RESULTS The patients receiving escitalopram treatment showed a significant improvement in GDS score from baseline (8.2±3.5) to 3 M (5.7±2.6, p = 0.04), and the patients receiving sertraline treatment showed a significant improvement in AS score from baseline (20.8±5.2) to 3 M (16.8±6.1, p = 0.05); however, no significant changes were noted in patients receiving nicergoline. CONCLUSION These results provide novel information on the efficacy of sertraline and escitalopram in the treatment of apathy and depression, respectively, in patients with AD.

中文翻译：

---

舍曲林，艾司西酞普兰和尼麦角林在阿尔茨海默氏病抑郁和无力感的治疗中的作用：冈山抑郁与无力感项目（ODAP）。

背景技术痴呆症的神经精神症状，例如阿尔茨海默氏病（AD）患者的抑郁和无知与生活质量降低相关。目的我们旨在确定两种抗抑郁药和一种抗病药在治疗AD患者抑郁症和冷漠中的功效。方法在本研究中，我们评估了舍曲林（n = 11；平均剂量= 31.8 mg），艾司西酞普兰（n = 13；平均剂量= 7.3 mg）和美麦角林（n = 9；平均剂量= 14.5 mg）的疗效。在3个月（M）的时间内治疗抑郁和无精神状态。33例AD患者表现出高老年抑郁量表（GDS）（> 5）或高无症状量表（AS）（> 16）评分。结果接受依他普仑治疗的患者的GDS评分从基线（8.2±3.5）显着改善至3 M（5.7±2.6，p = 0）。04），接受舍曲林治疗的患者的AS评分从基线（20.8±5.2）显着改善至3 M（16.8±6.1，p = 0.05）；然而，接受美麦角林的患者无明显变化。结论这些结果为舍曲林和依他普仑分别治疗AD患者的冷漠和抑郁提供了新的信息。